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ABSTRACT: Peptide toxins find use in medicine, biotechnology, and agriculture. They are exploited as
pharmaceutical tools, particularly for the investigation of ion channels. Here, we report the synthesis and
activity of a novel family of peptide toxins: the cystine-knotted α nemertides. Following the prototypic α-1 and
-2 (1 and 2), six more nemertides were discovered by mining of available nemertean transcriptomes. Here, we
describe their synthesis using solid phase peptide chemistry and their oxidative folding by using an improved
protocol. Nemertides α-2 to α-7 (2−7) were produced to characterize their effect on voltage-gated sodium channels (Blatella
germanica BgNaV1 and mammalian NaVs1.1−1.8). In addition, ion channel activities were matched to in vivo tests using an Artemia
microwell assay. Although nemertides demonstrate high sequence similarity, they display variability in activity on the tested NaVs.
The nemertides are all highly toxic to Artemia, with EC50 values in the sub-low micromolar range, and all manifest preference for the
insect BgNaV1 channel. Structure−activity relationship analysis revealed key residues for NaV-subtype selectivity. Combined with
low EC50 values (e.g., NaV1.1: 7.9 nM (α-6); NaV1.3: 9.4 nM (α-5); NaV1.4: 14.6 nM (α-4)) this underscores the potential utility of
α-nemertides for rational optimization to improve selectivity.
Animal peptide toxins associated with defense andpredation have long been exploited for medicinal,
agricultural, and biotechnological applications.1,2 Most of
those peptides originate from a limited number of taxa,
including cone snails, scorpions, spiders, and snakes. However,
many more animals make use of such compounds, and it is
clear that the study of toxins from carefully selected neglected
taxa yield new compounds with potent and interesting effects.3
In the current work, we characterize the effects of a novel
family of peptide toxins, the α-nemertides, as modulators of
voltage-gated sodium channels (NaV) and on Artemia salina.
These peptide toxins were discovered from one such
overlooked taxon: nemertean worms.
The phylum Nemertea comprises approximately 1350 valid
species worldwide.4 The majority of species are found in
marine environments, though some are freshwater dwelling
(22 species)5 and a few are terrestrial.6 Most of the known
species are predators or both predators and scavengers, and
they use their eversible proboscis to hunt for prey. Their
secretion is known to contain both proteinaceous and low
molecular weight toxins (recently reviewed)7 and include, for
example, peptide neurotoxins.8,9 Lately, transcriptomic and
genomic studies have revealed additional putative protein
toxins in nemertean worms, including possibly hemolytic ion
channel modulators (Na+, K+, Ca2+) and serine protease
inhibitors.8,10,11
Recently, we described the discovery of the prototypic
member of a family of peptide toxins, nemertide α-1 (1), from
the epidermal mucus of the nemertean worm Lineus long-
issimus.8 We showed that this conspicuous marine worm also
expressed the homologous nemertide α-2 (2), together with a
larger type of nemertides, called β-nemertides, on the peptide
level. By mining the nemertean transcriptomes available at the
time, seven full-length α-nemertides (α-1−7; 1−7) and one
truncated (α-8) one were identified. All these peptides are
concentrated to the Lineidean genera of nemerteans, Figure 1.
Nemertide α-1 (1) contains three disulfide bonds and folds
into the inhibitory cystine knot (ICK) motif. The structure is
compact, consisting of a series of turns and one stretch of
secondary structure: a short α-helix in loop 2, Figure 1A.
Residues Phe8, Trp22, and Phe24 form an aromatic patch on
one side of the molecule.8 Sequence similarity is high in the
family; for example 2−6 differ by only one or two substitutions
from 1, and three-dimensional structures can be assumed to be
highly similar, Figure 1. But what differences do these
variations confer in activity?
The functional characterization of nemertean peptide and
protein toxins is limited so far. Cytolytic and hemolytic effects
have been reported for A-cytolysin13 and parborlysin
proteins,14,15 and the 55-residue-long and helical neurotoxin
B-IV16 and nemertide α-1 (1) are paralytic and lethal to
crustaceans in sub-nmol/kg doses when injected.8,16−18
Mechanism of action has only been shown for α-1, which
binds to NaV channels with high affinity and selectivity,
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although sodium ion channels have also been suggested to be
the target for neurotoxin B-IV.16 Nemertide α-1 (1) was found
to be exceptionally toxic to green crabs (Carcinus maenas,
lethal at doses above ∼300 pmol/kg) and to cockroaches
(Blaptica dubia, lethal at 2 nmol/kg). Furthermore, the toxin
was shown to modulate insect NaVs at low nanomolar
concentrations and mammalian NaVs in the μM range,
8
suggesting a possible use for these peptides as bioinsecti-
cides.19 This observation is supported by a recent study where
pro-alpha-1 was expressed and tested against a selection of
insects, demonstrating oral toxicity to aphids and brassica
moths.20
In the current work, we report the synthesis, oxidative
folding, and functional characterization of native members of
the α-nemertide family of peptide toxins. All peptides show
activity on Artemia salina, and their activity on voltage-gated
sodium channels of both invertebrate and vertebrate origin
reveals selectivity as well as structure−activity relationships.
■ RESULTS AND DISCUSSION
Synthesis and Folding of Nemertides. Only two of the
α-nemertide toxins (1, 2) have been detected as peptides from
natural sources, whereas the discovery of the other five full-
length peptides is the result of transcriptome mining.
Previously,8 we showed that at least 1 is amenable for peptide
synthesis: here we demonstrate that the full family can be
made using FMOC-based solid phase peptide synthesis
(SPPS), with good yields and purity. All α-nemertides were
considered to contain Hyp residues in the C-terminus based
on the native 1 and 2.8
In analogy with our previous work, 2 was assembled on
HMPA resin using automated SPPS on a CEM Liberty1
microwave-assisted synthesizer.8 Although this high-swelling
resin generally results in good yields, it comes with the
practical problem of sometimes blocking drain tubing of the
reaction vessel, resulting in stops in the sequence of reactions
as well as high maintenance load. Nemertides 3−6 were
therefore assembled on 2-chlorotrityl resin (Iris Biotech
Marktredwitz, Germany), and 7 was purchased from GenScript
(Piscataway, NJ, USA) in reduced form. Yields and purities
were similar for 3 and 4 compared to the previous synthesis of
1,8 with the target peptides as the major product as judged by
HPLC-UV. The synthesis of 5 and 6 gave a higher degree of
impurities after cleavage.
The protocol for oxidative folding was substantially
improved from previous work.8 Notably, extra caution was
taken to completely dissolve peptides first in water, followed by
addition of DMSO prior to mixing into the folding buffer. No
precipitation and/or aggregation of peptides were observed
using this procedure for any peptide. We presume that the
overall fold of peptides and disulfide connectivity are the same
within this peptide family and that all peptides follow the same
folding pattern as 1 and 2. The presumption that peptides 3−7
have the overall structure in common with 1 and 2 is further
supported by their bioactivity as described below. Then, all
correctly folded nemertides 1−6 were distinguished from
misfolded variants by eluting as a distinct peak late in the
chromatogram. Only 7 displayed a more complex folding
pattern, where the main product required further purification
(using repetitive RP-HPLC).
All folded nemertides were purified to >95% as judged by
HPLC-UV (215 nm), Figure S1. Typical HPLC-UV chromato-
grams for crude peptide (cleaved), folding mixture after 15 h,
and purified folded peptide are shown in Figure 2. Identities of
the purified peaks were analyzed using UPLC-QToF. Expected
monoisotopic masses were calculated and compared to the
experimental masses obtained from deconvolution of the 4z
ions; all experimental masses show errors of less than 10 ppm
(Table 1).
Small Sequence Differences Modulate Physicochem-
ical Properties of Nemertide α Peptides. Nemertides 2−6
were co-injected on the UPLC-QToF (using a C18 column) to
evaluate the hydrophilicity. Peptide 7 was not evaluated in
these experiments due to its limited availability. All five toxins
(2−6) eluted between 17 and 22 min in the system used, in
the elution order 3, 2, 6/4, and 5 (Figure 3). The order of
elution reflects changes in the aromatic patch comprising
residues in positions 8, 22, and 24; the early eluting 2 and 3
lack an aromatic amino acid in position 8. Furthermore,
peptide 3 contains a basic residue Lys4, explaining the early
elution at low pH. The elution order of 4, 5, and 6 may also be
Figure 1. Nemertide structure, sources, and sequences. (A) Solution
NMR structure of nemertide α 1 (PDB id 6ENA). The three disulfide
bonds at the core of the molecule are numbered (in Roman numerals)
and marked in yellow. Numerals mark the loops. (B) Schematic
phylogenetic tree of α nemertide expressing species identified on the
transcriptomic level. The tree is redrawn from Ament-Velaśques et al.
2016.12 *: No α nemertide was found in L. viridis. (C) Top:
consensus α nemertide sequence with the variable positions marked
as numbers. Roman numerals mark cysteines, and the ICK disulfide
connectivity (I−IV, II−V, III−VI) is displayed with black bars. Loop
number in numerals; number of residues in parentheses. Bottom:
Sequence alignment of nemertides, including the truncated α-8. P*:
hydroxyproline (Hyp). With the exception of 1 and 2, the α
nemertides have so far been identified only in transcriptomic data
from the marine Lineideae family of nemertean worms (genus: Lineus:
4 sp., Ramphogordius: 1 sp., and a partial sequence in Riseriellus: 1 sp.)
The partial contig of 8 from the R. occultus transcriptome was omitted
from this study since the full C-terminal sequence was unknown.
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explained by residues in position 4: 6 has a Lys and elutes first
of the three, shortly followed by 4 with a hydroxyl-containing
Ser in that position. Nemertide α-5 elutes last, with an aliphatic
Ala at position 4. The basic Lys/His25 does not seem to
influence the retention order on the column.
Activity on Brine Shrimps Distinguishes Two Groups
of α-Nemertides. The clear and rapid effect of toxins on
green crabs (C. maenas) was a key to their discovery; however
the use of these relatively large crustaceans is highly dependent
on availability and season. We therefore selected an alternative
in vivo assay based on the brine shrimp, Artemia salina, as a
substitute. Artemia are small in size, and the assay can be
performed in a microwell format using minimal amounts of
toxin.21 The readout of the assay was the lethality after 24 h,
and larvae were not followed over time. However, at the
highest concentrations effects could be observed within
minutes, with larvae going into a convulsive state followed
by death.
All tested α-nemertides (1−7) exhibit high toxicity to
Artemia, with EC50 values in the sub to low μM range.
Furthermore, the activity distinguishes the tested α-nemertides
into two groups: 1, 4, and 5 display EC50 values in the sub μM
range (0.3, 0.4, and 0.4 μM, respectively), whereas 2, 3, 6, and
7 have EC50 values 1 order of magnitude higher (2.9, 4.7, 2.8,
and 6.1 μM, respectively). EC50 curves are shown in Figure 4.
α-Nemertides Show Potent and Differing Effects on
NaV Channels. All peptides (1−7) display potent activity on
NaV channels, and current results demonstrate structure−
activity relationships. They all show the highest activity on
insect BgNaV1: 1 and 4−7 display EC50 values in the low nM
range (2.6−11.1 nM), whereas 2 and 3 are approximately one
order of magnitude less active. The most active of them all is 6.
EC50 values of all peptides against all ion channels tested are
shown in Table 2. To simplify comparison, EC50 values have
been normalized to the most active peptide in Supplementary
Table 1 and their activity on BgNaV1.
Nemertide α-6 (6) also displays the most potent activity of
all peptides on mammalian ion channels, with an EC50 of 7.9
nM on Nav1.1. This is one order of magnitude higher activity
than the effect observed for any other toxin: 1−5 and 7 has
EC50 values in the range of 92−125.8 nM on Nav1.1.
Nemertide α-6 (6) differs from the other α-nemertides by
having the combination of Lys at position 4 and Phe at
position 8. It is also the most potent peptide (EC50 24.3 nM)
on Nav1.2. Notably, the prototypic α-1 (1) is the least active
peptide on this particular ion channel (EC50 359.6 nM), and
this is also the highest EC50 value for 1 on all of the tested
NaVs.
On the NaV1.3 channel, 4 and 5 exhibit substantially higher
activity than other peptides. These two peptides also show high
potency against NaV1.4, but notably the effect of 5 is one order
of magnitude lower than that of 4 to NaV1.5.
The largest differences between peptides on any ion channel
are seen for NaV1.4, ranging from the EC50 of 4 at 14.6 nM to
2 with an EC50 of 1150.3 nM. In contrast, the differences in
activity are smallest on NaV1.5. On NaV1.6, 2 exhibits an EC50
(1361.8 nM) one order of magnitude higher than 1, 4, and 7
and 2 orders of magnitude higher than 3, 5, and 6. Nemertide
6 is the most potent, with an EC50 of 36.3 nM. On NaV1.7, 2 is
the least active toxin by far, with an EC50 value of 1296.7 nM.
Figure 2. Analytical HPLC-UV traces from synthesis, folding, and
final purification of nemertide α 4. To the left, schematic view of the
composition of peptide content. Top: Trace from cleavage of 4 from
resin. Middle: Trace from oxidative folding after 15 h. Bottom: Pure
folded 4. *Product wanted in each step. Note that the chromato-
graphic systems differ for the different chromatograms, hence the drift
in retention time for the folded 4. The peaks at ∼24 (top) and 30 min
(middle and bottom) are connected to the gradient.
Table 1. Theoretical and Experimental Molecular Mass
Values for α 2−7a
expected (Da) experimental (Da) delta (Da)
2 3259.3415 3259.3607 0.0192
3 3274.3523 3274.3783 0.0260
4 3323.3363 3323.3683 0.0320
5 3316.3055 3316.3371 0.0316
6 3373.3631 3373.3635 0.0004
7b 3328.7969 3328.35 0.45
aTheoretical and experimentally determined deconvoluted (4z)
masses for α 2−6. The 4z ion was chosen since it falls within the
calibrated mass range for the QToF used. All values for 2−6 are
within 10 ppm of the expected masses. bFor 7, only low-resolution
MS (LCQ deca) was available; the convoluted mass was calculated for
the doubly charged average mass ion.
Figure 3. Base peak intensity chromatogram of a mixture of the
nemertides 2−6. 3 elutes at 17.7 min, 2 elutes at 19.3 min, and 6 and
4 elute at 20.9−21.0 min. 5 elutes at 21.5 min. The time axis is
truncated to show 17 through 23 min. Nemertide α-1 was not
included in this experiment, but elutes after 2 in a similar system.8
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All other α-nemertides (1, 3, 4, 6, 7) exhibit comparable EC50
values on NaV1.7.
Sequence, Structure, and Activity of Nemertean α
Peptide Toxins. In the present investigation, we verified that
small differences in the amino acid (AA) sequences may have a
profound effect on the peptide syntheses, folding, and
biological activities. Comparing AA sequences in detail
shows that the α-nemertides discovered so far vary at only
seven out of 31 amino acids, positions 4, 5, 8, 11, 13, 25, and
28, as highlighted in Figure 5. Positions 4 (Ala, Lys, Ser, Pro),
5 (Thr, Val), and 8 (Phe, Val, Gly, Met) are all situated in loop
1 between Cys residues I and II. Loop 2, i.e., the sequence
Figure 4. Effect of α-nemertides in the Artemia microwell assay. 1, 4, and 5 have EC50 values in the range 0.3−0.4 μM. 2, 3, 6, and 7 have average
EC50 values in the range 2.8−6.1 μM. All experiments were performed in duplicate, except 7, which was done in triplicate. All data points are shown
in the graphs (dots), with average fitted values plotted as a line. Vertical dotted lines display the EC50s.
Table 2. EC50 Values (nM) of 1−7 in NaV1.1−1.8 and BgNav1a
BgNav1 Nav1.1 Nav1.2 Nav1.3 Nav1.4 Nav1.5 Nav1.6 Nav1.7 Nav1.8
α-1 8.6 ± 2.9 124.1 ± 28.7 359.6 ± 89.8 135.4 ± 76.3 145.5 ± 57.5 138.3 ± 25.5 240.4 ± 22.3 76.5 ± 33.9 n.a.
α-2 87.2 ± 10.5 125.8 ± 43.6 97.9 ± 23.2 127.7 ± 44.5 1150.3 ± 217.8 149.2 ± 89.1 1361.8 ± 115.2 1296.7 ± 232.4 n.a.
α-3 97.5 ± 15.6 125.8 ± 43.6 137.8 ± 36.5 138.9 ± 63.2 150.2 ± 72.7 108.4 ± 5.9 92.8 ± 11.2 102.2 ± 5.8 n.a.
α-4 11.1 ± 1.6 92.0 ± 38.8 134.2 ± 34.0 12.9 ± 3.2 14.6 ± 3.6 27.8 ± 4.3 123.6 ± 29.7 80.5 ± 28.3 n.a.
α-5 7.8 ± 3,2 102.1 ± 50.2 156.1 ± 10.5 9.4 ± 3.7 15.4 ± 5.4 132.7 ± 21.8 66.9 ± 8.2 73.0 ± 14.1 n.a.
α-6 2.6 ± 0.3 7.9 ± 1.3 24.3 ± 2.3 105.6 ± 54.9 46.4 ± 7.2 215.2 ± 63.6 36.3 ± 4.3 97.2 ± 8.3 n.a.
α-7 9.5 ± 1.2 171.5 ± 61.6 50.4 ± 16.1 170.2 ± 39.5 810.6 ± 130.4 155.6 ± 18.3 147.6 ± 53.6 129.0 ± 24.6 n.a.
aAll experiments were run in triplicate. bn.a.: not active.
Journal of Natural Products pubs.acs.org/jnp Article
https://doi.org/10.1021/acs.jnatprod.1c00104
J. Nat. Prod. 2021, 84, 2121−2128
2124
between Cys II and III, has two variable positions: 11 (Leu,
Ile) and 13 (Lys, Asn). Loop 3 is fully conserved, whereas loop
4 contains the variable position 25 (Lys, His, and Ala of α-8).
The N-terminal “loop” contains only a conserved Gly residue,
whereas the C-terminal stretch contains five amino acids, one
of which is the variable position 28 (Hyp, Lys). When
comparing all peptides, 7 is the most divergent of the toxins,
harboring seven substitutions from the consensus sequence.
The pairwise alignment of 1−6 varies between 90.3% (2 vs 6)
and 96.7%, whereas α-7 has between 77% and 80% identity, vs
1−4 and 5/6. The most frequent variable positions (4, 8, and
25) are all positioned on the same side of the peptide, where
loops 1 and 4 meet, Figure 6.
All α-nemertides tested display potent effects in Artemia and
in NaV assays. The combined results indicate grouping of
peptides: 1, 4, and 5 showed higher activity against both
Artemia and BgNaV1, compared to 2 and 3. The Artemia assay
clearly divides α-nemertides into two groups: the highly active
1, 4, and 5 (EC50 0.3−0.5 μM) and moderately active toxins 2,
3, 6, and 7 (EC50 2.8−6.1 μM). The most active (1, 4, 5) all
contain a small amino acid (Ala or Ser) in position 4 in
combination with Phe8, whereas 3 and 6 with lower activity
have a basic Lys in position 4. Furthermore, 2 and 3 lack an
aromatic residue in position 8. Nemertide 6 shows high activity
in the BgNaV assay, but not in the Artemia microwell assay.
α-Nemertides appear to always be expressed at least in pairs
on the transcriptomic level. Evidence of coexpression on the
peptide level has so far only been demonstrated in L.
longissimus, in which 1 and 2 were found to be present
together in the mucus.8 Transcriptome analyses indicate that 1
is present together with 2 in both L. longissimus and L. ruber. L.
ruber also expresses 7. In L. lacteus, 1 is paired with 3. The
results from the assays reveal that these “pairs” are composed
of toxins of different potency. For example, 1 is one order of
magnitude more potent both in the Artemia assay and at the
BgNaV channel as compared to 2 and 3. The same pattern can
be observed in other pairs: the highly potent 5 occurs together
with the less potent 3 in R. pseudolacteus, and in the case of L.
sanguineus, 4 is paired with 6. Both of these toxins are
approximately equipotent at BgNaV1; 4 is however one order
of magnitude more active in Artemia. Nemertide α-7 (7) found
in the L. ruber transcriptome was the least active peptide in
Artemia. It does however exhibit similar activity in BgNaV1 as
compared to α-1 (1). The pairwise expression of α-nemertides
with differing activity profiles suggests that these peptides may
target different prey or predators.
Most of the α-nemertides display higher activity on the
cockroach BgNaV1 channel than on the mammalian subtypes
tested, which becomes more evident when comparing potency
ratios (see Table 2 and the normalized values in
Supplementary Table 1). This is especially pronounced for 1,
where the EC50 for BgNaV1 is at least nine times lower than in
the other channels tested. In contrast, 3 displays virtually no
difference in EC50 between the different NaVs including
BgNaV1. The results suggest a possibility to tailor sequences to
achieve a more specific selectivity profile, and some initial
conclusions may be drawn from the native sequence variations
in combination with the activity profiles. For example, 1 and 2
differ in position 8 only, containing Phe and Val, respectively,
which makes up part of the aromatic patch. The difference is
clear in the Artemia assay: 1 is approximately 10 times more
active, demonstrating the importance of a hydrophobic/
aromatic residue. Also in the NaV screening, clear differences
are evident; the change from Phe to Val causes loss in activity
by at least 1 order of magnitude in the following NaV subtypes:
BgNaV1, NaV1.4, NaV1.6, and NaV1.7. A 3-fold increase in
activity is observed for NaV1.2, while no difference is apparent
for NaV1.1, NaV1.3, and NaV1.5.
At position 4, an increase in activity is observed when Ala
(as in 1) is exchanged to Ser (as in 4) for NaV1.3, NaV1.4, and
NaV1.5, while almost no differences are observed for the
remaining subtypes. The influence of a basic Lys in that
position (as in 6) is deducible in the comparison between 5
(Ala4, His25) and 6 (Lys4, His25). A Lys residue at position 4
results in a loss in activity of 1 order of magnitude in the
Artemia assay. In the NaV assays, it results in a strong increase
Figure 5. Nemertide α sequence variation and species. Consensus
sequence alignment of variable positions. Alignment of the variable
positions (positions 4, 5, 8, 11, 13, 25, and 28) of α-nemertides.
Species where α-nemertides are found: L. la, L. lacteus; L. lo, L.
longissimus; L. ru, L. ruber; L. sa, L. sanguiens; R. ps, R. pseudolacteus. 1
is found in three species, and 2 and 3 are found in two species each.
4−7 are found in one species each. All investigated species contain
two α-nemertide sequences, except L. ruber, which harbors three. P*,
hydroxyproline.
Figure 6. Ribbon and surface representations of 1 (RCSB pdb id:
6ENA) with the variable positions between the family members
marked. Red: Positions with the highest frequency of variability: 4
(AKSP), 8 (FVGM), and 25 (KH). Blue: Positions that only differ
from the archetype α sequence in α-7; positions 5 (V), 11 (I), 13 (N),
and 28 (K). All red-colored positions (4, 8, 25) are situated on the
same side of the molecule. Figure prepared in UCSF Chimera.22
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in activity at NaV1.1 and NaV1.2. Interestingly, a loss in activity
by 1 order of magnitude is observed for NaV1.3, while almost
no change in activity is observed for the remaining channels,
including BgNaV1. Position 25 (consensus, 1, Lys) can be
compared to 5 (His), with a pronounced increase in activity
for NaV1.3 and NaV1.4. In NaV1.6 a 4-fold increase in activity is
observed in favor of His25, while almost no difference is
observed for BgNaV1, NaV1.1, NaV1.2, NaV1.5, and NaV1.7.
Use and Role of α-Nemertides. Do any of these
compounds appear to be possible hits for further studies of
applications in medicine or agriculture? Among the NaV
channels, NaV1.7 has been in particular focus for pain
control.23,24 Neither of the nemertides tested here display
especially remarkable activity nor high selectivity against this
channel subtype. NaV1.3 is also of interest for pain control;
here 5 shows high activity (9.4 nM). Interestingly, this peptide
is 10-fold less active on NaV1.5, which may be important, as
unwanted effects on this ion channel are of special concern
because NaV1.5 is predominantly expressed in heart muscle.
Notable is also the effect of 6, as NaV1.1 is a target in
epilepsy.25 Nemertide 6 is also the most favorable peptide with
reference to activity on Nav1.5. However, the notorious
Nav1.5 may now emerge as a potential drug target. Recently,
Nijak et al. showed that nemertide 1 was able to restore the
loss of function by reducing channel inactivation by binding to
NaV1.5 in a rare inherited cardiac arrhythmia.
26 Nemertide 4,
which normally would be immediately disqualified as the most
toxic peptide because it is the most active on NaV1.5, might
thus be the most interesting one.
Judged from activity in vivo, 1 still appears as one of the most
promising insecticidal peptides, but in the BgNaV1 assay 6
again stands out as the most active compound. This leads to
another question: why are the effects of some peptides
predictable between in vitro and in vivo, whereas others are
not? Nemertide 6 contains a Lys at position 4, adding an extra
positive charge to the molecule. This could possibly indicate a
bioavailability threshold. Lys4 can also be found in 3, which
has relatively low activity both in Artemia and at the BgNaV1
channel. Nemertides 2 and 3, with low activity in both Artemia
and BgNaV1, both lack a Phe in position 8, indicating an
important position for insect/crustacean activity. Together, the
combined results from 2, 3, and 6 indicate that a Lys in
position 4 mainly affects the bioavailability in Artemia, while a
Phe at position 8 is important for the actual effect at the
channel.
The role of these peptides in nature is still unclear. Most ion
channel toxins are described as parts of venoms,27 but the roles
of nemertean toxins can be dual. All five species for which full-
sequence α-nemertides have been identified also express both
cytolysins/parborlysins and neurotoxin B/β-homologues on
the transcriptomic level.7,8 All three toxin types have been
identified in the secreted mucus and may be part of the same
defense/predatory system, where the cytolysins/parborlysins
may facilitate uptake of the neurotoxins into the intended
prey/aggressor or be part of the protection against malevolent
microorganisms.
■ EXPERIMENTAL SECTION
Synthesis of α-Nemertides 1−7. Nemertides α-1−6 were
assembled in 0.1 mM scale using Fmoc-chemistry-based automated
SPPS essentially according to our previously described method for the
synthesis and cleavage of α-1,8 with the following differences: for 3−6,
2-chlorotrityl resin was utilized instead of the high-swelling HMPA
resin previously used. Nemertides α-3−6 were assembled on 2-
chlorotrityl in 0.1 mmol scale, with the first four amino acids
(positions 31−28) coupled manually. The first amino acid (Gln) was
loaded at 0.7 equiv using DIPEA as coupling reagent, and the
unoccupied binding sites were capped using MeOH. The following
Asn residue (5 equiv) was double-coupled with DIC (10 equiv) and
OxymaPure (10 equiv). All hydroxyprolines were double-coupled
using 3 equiv of amino acid. The resin was then transferred to a
microwave peptide synthesizer (Liberty 1, CEM Corp., Matthews,
NC, USA) for the remaining coupling cycles except a manually
introduced dipeptide at positions 11 and 12 (Leu-Ser; using 2 equiv).
Peptides were cleaved off the resin by the addition of TFA/H2O/
TIPS (95:2.5:2.5), precipitated in ice-cold ether, redissolved in
MeCN/H2O (1:1), lyophilized, and purified using RP-HPLC.
Nemertide α-7 was purchased from GenScript in reduced form.
All peptides were oxidatively folded in batches of 20−25 mg:
peptides were dissolved in a total of 6 mL MQ-water added in small
portions with rigorous vortexing in between. DMSO (2 mL) was
added to the fully dissolved peptide, and the solution was slowly
added to 92 mL of 0.54 M NH4HCO3 containing 20% DMSO, 0.5
mM GSH, and 2.6 mM GSSG, yielding a final folding buffer of 100
mL of 0.5 M NH4HCO3, 20% DMSO, 0.45 mM GSH, and 2.4 mM
GSSG. The folding mixture was put on a shaking table for 15−18 h.
Folding was quenched by addition of 200 mL of 0.4% TFA in MQ-
water.
Purification of the folded peptides was performed on RP-HPLC in
accordance with our previous work,8 using preparative RP-HPLC on a
Jupiter C18 column (300 Å 250 × 21.2 mm 10, Phenomenex, CA,
USA) run in linear gradient mode (5−95% MeCN, 0.05% TFA in 45
min, 16 mL/min). Fractions (0.8 min) were collected, and a small
sample of each fraction was analyzed by direct infusion into an LCQ-
Deca MS (Thermo Electron, CA, USA) to identify toxin-containing
fractions. The purity of selected fractions was assessed by HPLC-UV
using a Kinetex XB-C18 column (C18, 250 × 4.6 mm, 5 μ, 100 Å,
Phenomenex) (6, 7) or a Jupiter column (C18, 250 × 4.6 mm, 5 μ,
300 Å, Phenomenex) (1−5). High-resolution MS was measured using
UPLC-QToF (Waters nanoAcquity; Micromass QToF Micro;
Waters, MA, USA). Quantification of the lyophilized pure, folded
peptides was performed using IR spectroscopy (DirectDetect,
Millipore Corp., MA, USA).
Microwell Artemia Bioassay. The Artemia microwell assay was
previously described.21 In short, Artemia cysts (Artemio pur, JBL,
Neuhofen, Germany) were hatched in a separation funnel containing
artificial seawater (33 g salt/L, Coral pro salt, Red Sea, Eilat, Israel)
prepared in deionized water. A small aquarium air pump was used to
aerate the water until the shrimp were harvested (24 h, RT).
Aliquots of 100 μL (0.003−300 μM nemertide in MQ-water,
control: 100 μL of MQ-water) were added in duplicates to flat-
bottom 96-well plates (cat. no.: nunc 260895, Thermo Fisher
Scientific, Waltham, MA, USA). Artemia nauplii, 10−15 in 100 μL of
salt water, were transferred to the wells and incubated at RT in the
dark for 24 h. Wells were then examined under a microscope, and all
dead and immobilized nauplii were counted. The surviving nauplii
were sacrificed by addition of 100 μL of MeOH, followed by 15 min
of incubation. The total numbers of nauplii were subsequently
counted. Toxicity was calculated as % dead or immobilized/total
nauplii in each well. Results were plotted in GraphPad prism 8. EC50
values were calculated using nonlinear regression.
Electrophysiology on Selected NaVs. For the expression of NaV
channels (hNav1.1, rNaV1.2, rNaV1.3, rNaV1.4, hNaV1.5, mNaV1.6,
hNav1.7, rNaV1.8, the insect channel BgNaV1, the auxiliary subunits
rβ1, hβ1, and TipE) in Xenopus laevis oocytes, the linearized plasmids
were transcribed using the T7 or SP6 mMESSAGE-mMACHINE
transcription kit (Ambion, Carlsbad, CA, USA). The harvesting of
stage V and VI oocytes from an anaesthetized female X. laevis frog was
described previously.28 Oocytes were injected with 50 nL of cRNA at
a concentration of 1 ng/nL using a microinjector (Drummond
Scientific, Broomall, PA, USA). The oocytes were incubated in a
solution containing 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 2 mM
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MgCl2, and 5 mM HEPES (pH 7.4), supplemented with 50 mg/L
gentamycin sulfate.
Two-electrode voltage-clamp recordings were performed at room
temperature (18−22 °C) using a Geneclamp 500 amplifier
(Molecular Devices, Downingtown, PA, USA) controlled by a
pClamp data acquisition system (Axon Instruments, Union City,
CA, USA). Whole cell currents from oocytes were recorded 1−4 days
after injection. The bath solution composition was 96 mM NaCl, 2
mM KCl, 1.8 mM CaCl2, 2 mM MgCl2, and 5 mM HEPES (pH 7.4),
5 (pH 7.4). Voltage and current electrodes were filled with 3 M KCl.
Resistances of both electrodes were kept between 0.8 and 1.5 MΩ.
The elicited currents were filtered at 1 kHz and sampled at 20 kHz
using a four-pole low-pass Bessel filter. Leak subtraction was
performed using a −P/4 protocol. For the electrophysiological
analysis of toxins, a number of protocols were applied from a holding
potential of −90 mV with a start-to-start interval of 0.2 Hz. Sodium
current traces were evoked by 100 ms depolarizations to Vmax (the
voltage corresponding to maximum sodium current in control
conditions). To assess the concentration−response relationships,
data were fitted with the Hill equation: y = 100/[1 + (EC50/
[toxin])h], where y is the amplitude of the toxin-induced effect, EC50
is the toxin concentration at half-maximal efficacy, [toxin] is the toxin
concentration, and h is the Hill coefficient. All data were tested for
normality using a D’Agustino Pearson omnibus normality test and for
variance using Bonferroni’s test or Dunn’s test. Data following a
Gaussian distribution were analyzed for significance using one-way
ANOVA. Nonparametric data were analyzed for significance using the
Kruskal−Wallis test. Differences were considered significant if the
probability that their difference stemmed from chance was below 5%
(p < 0.05). All data were analyzed using pClamp Clampfit 10.0
(Molecular Devices) and Origin 7.5 software (Originlab, North-
ampton, MA, USA).
The use of the frogs was in accordance with license number
LA1210239 of the Laboratory of Toxicology & Pharmacology,
University of Leuven. All animal care and experimental procedures
were in accordance with the guidelines of “European convention for
the protection of vertebrate animals used for experimental and other
scientific purposes” (Strasbourg, 18.III.1986).
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